View Older Stories View More Recent Stories
-
FDA awards priority vouchers to two investigational drugs
-
Merck agrees with US government to expand medicine access and cut costs
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Trump to announce prescription drug price agreements
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
FDA to fast-track reviews of two Merck drugs under commissioner national priority voucher pilot program - Reuters
-
Merck reports positive results for KEYTRUDA plus Padcev in bladder cancer
-
Merck gets EU committee backing for expanded WINREVAIR use in PAH
-
FDA launches fresh safety scrutiny of approved RSV therapies for infants - Reuters
-
Merck (MRK) PT Raised to $122 at Guggenheim
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
FDA conditionally approves Merck's cattle parasite treatment product
-
Top drug regulator Richard Pazdur set to leave FDA - Stat
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Merck receives FDA fast track for Alzheimer's drug MK-2214
-
Merck (MRK) call put ratio 2.5 calls to 1 put as share price up 3.6%
-
MERCK to present hematology pipeline data at ASH 2025 meeting
-
Wells Fargo Upgrades Merck (MRK) to Overweight
-
FDA approves Padcev plus Keytruda for certain patients with bladder cancer
-
FDA approves Keytruda and Padcev combo for bladder cancer treatment
-
European Commission approves subcutaneous KEYTRUDA for all adult indications
-
Merck (MRK) Declares $0.85 Quarterly Dividend; 3.5% Yield
-
Merck to acquire Cidara for $9.2 billion to gain influenza drug
-
Merck (MRK) call put ratio 4.6 call1 to 1 put
-
Merck (MRK) Nearing Deal To Buy Cidara Therapeutics- FT
-
Analysts cautious following Merck’s CMD, Morgan Stanley flags near-term risks
-
Merck (MRK) PT Raised to $114 at Leerink Partners
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Merck (MRK) Tops Q3 EPS by 23c; narrows forecast
-
Stocks expected to have increasing option volume: MRK LLY GILD MA STLA HSY RDDT CI MSTR AMZN AAPL CMG WOLF
-
Merck (MRK) call put ratio 2.3 calls to 1 put into quarter results
-
European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
-
Merck drug combination meets cancer trial endpoint in kidney cancer study
-
WELIREG plus LENVIMA meets key endpoint in kidney cancer trial
-
Merck to present phase 3 results for oral PCSK9 inhibitor at AHA meeting
-
Merck presents data on pneumococcal vaccine coverage at IDWeek
-
Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
-
Merck begins construction of $3 billion manufacturing facility in Virginia
-
Citi Resumes Merck (MRK) at Neutral
-
Merck presents cancer research data at ESMO 2025 congress
-
Merck (MRK) there is no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots
-
Merck starts phase 2b trials for tulisokibart in three new conditions
-
Merck (MRK) call put ratio 2.6 calls to 1 put with a focus on October 3 weekly calls
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
